These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 27491402

  • 1. EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.
    De Mello RA, Liu DJ, Aguiar PN, Tadokoro H.
    Recent Pat Anticancer Drug Discov; 2016; 11(4):393-400. PubMed ID: 27491402
    [Abstract] [Full Text] [Related]

  • 2. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 3. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
    Singhi EK, Horn L, Sequist LV, Heymach J, Langer CJ.
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
    [Abstract] [Full Text] [Related]

  • 4. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE, Gandhi L, Costa DB.
    Am Soc Clin Oncol Educ Book; 2014 Jan; ():e353-65. PubMed ID: 24857124
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
    Tartarone A, Lazzari C, Lerose R, Conteduca V, Improta G, Zupa A, Bulotta A, Aieta M, Gregorc V.
    Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
    [Abstract] [Full Text] [Related]

  • 6. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M, Costa DB, Rangachari D.
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [Abstract] [Full Text] [Related]

  • 7. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N.
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [Abstract] [Full Text] [Related]

  • 8. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.
    Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A.
    BMC Cancer; 2013 May 29; 13():262. PubMed ID: 23714228
    [Abstract] [Full Text] [Related]

  • 9. [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
    Hamard C, Ruppert AM, Lavole A, Rozensztajn N, Antoine M, Cadranel J, Wislez M.
    Ann Pathol; 2016 Jan 29; 36(1):63-72. PubMed ID: 26775573
    [Abstract] [Full Text] [Related]

  • 10. Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
    Nishimura T, Nakamura H.
    Adv Exp Med Biol; 2016 Jan 29; 926():115-137. PubMed ID: 27686809
    [Abstract] [Full Text] [Related]

  • 11. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.
    Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, Palazzolo G, Bareschino MA, Schettino C, Sacco PC, Ciadiello F, Gridelli C.
    Curr Med Chem; 2012 Jan 29; 19(20):3337-52. PubMed ID: 22664249
    [Abstract] [Full Text] [Related]

  • 12. ALK inhibitors and advanced non-small cell lung cancer (review).
    Rossi A, Maione P, Sacco PC, Sgambato A, Casaluce F, Ferrara ML, Palazzolo G, Ciardiello F, Gridelli C.
    Int J Oncol; 2014 Aug 29; 45(2):499-508. PubMed ID: 24889366
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
    Katayama R, Lovly CM, Shaw AT.
    Clin Cancer Res; 2015 May 15; 21(10):2227-35. PubMed ID: 25979929
    [Abstract] [Full Text] [Related]

  • 14. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
    Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, Puccetti M, Capelli L, Calistri D, Verlicchi A, Gamboni A, Papi M, Mariotti M, De Luigi N, Scarpi E, Bravaccini S, Turolla GM, Amadori D, Crinò L, Delmonte A.
    Clin Lung Cancer; 2016 Sep 15; 17(5):384-390. PubMed ID: 26712101
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN, Zhang XC, Chen HJ, Zhou Q, Yan LX, Xie Z, Su J, Chen ZH, Tu HY, Yan HH, Wang Z, Xu CR, Jiang BY, Wang BC, Bai XY, Zhong WZ, Wu YL, Yang JJ.
    Oncotarget; 2016 Oct 04; 7(40):65185-65195. PubMed ID: 27533086
    [Abstract] [Full Text] [Related]

  • 16. Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.
    Dong X, Fernandez-Salas E, Li E, Wang S.
    Neoplasia; 2016 Mar 04; 18(3):162-71. PubMed ID: 26992917
    [Abstract] [Full Text] [Related]

  • 17. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C.
    Curr Clin Pharmacol; 2016 Mar 04; 11(2):77-87. PubMed ID: 27138017
    [Abstract] [Full Text] [Related]

  • 18. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT, Solomon B.
    Clin Cancer Res; 2011 Apr 15; 17(8):2081-6. PubMed ID: 21288922
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
    Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim SM, Kim H, Kang HN, Lee JM, Kim SG, Park CW, Chang H, Shim HS, Lee HW, Cho BC.
    J Thorac Oncol; 2017 Mar 15; 12(3):491-500. PubMed ID: 27836576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.